Neurocrine Biosciences to present at two major investor conferences in June 2026.

Neurocrine Biosciences announced that its executives will participate in two upcoming investor events: the William Blair 46th Annual Growth Stock Conference on June 2, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. These presentations will include fireside chats and will be webcast live, with replays available on the company's website. Neurocrine Biosciences is a biopharmaceutical company focused on developing treatments for neurological, psychiatric, endocrine, and immunological disorders, with several FDA-approved therapies and a robust pipeline. These events provide an opportunity for investors to learn more about the company's progress and future plans.